Company Analysis Veracyte, Inc.
1. Summary
Advantages
- The stock's return over the last year (-0.8792%) is higher than the sector average (-43.06%).
- Current debt level 3.9% is below 100% and has decreased over 5 years from 4.94%.
Disadvantages
- Price (42.84 $) is higher than fair price (5.09 $)
- Dividends (0%) are below the sector average (0.5195%).
- The company's current efficiency (ROE=2.17%) is lower than the sector average (ROE=103.63%)
Similar companies
2. Share price and performance
2.1. Share price
2.3. Market efficiency
| Veracyte, Inc. | Healthcare | Index | |
|---|---|---|---|
| 7 days | -4% | -0.8% | -1.3% |
| 90 days | 38.7% | -41.7% | 5.1% |
| 1 year | -0.9% | -43.1% | 17% |
VCYT vs Sector: Veracyte, Inc. has outperformed the "Healthcare" sector by 42.18% over the past year.
VCYT vs Market: Veracyte, Inc. has significantly underperformed the market by -17.84% over the past year.
Stable price: VCYT is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.
Long period: VCYT with weekly volatility of -0.0169% over the past year.
3. Summary of the report
5. Fundamental Analysis
5.1. Stock price and price forecast
Above fair price: The current price (42.84 $) is higher than the fair price (5.09 $).
Price is higher than fair: The current price (42.84 $) is 88.1% higher than the fair price.
5.2. P/E
P/E vs Sector: The company's P/E (129.53) is higher than that of the sector as a whole (-268.1).
P/E vs Market: The company's P/E (129.53) is higher than that of the market as a whole (-76.8).
5.2.1 P/E Similar companies
5.3. P/BV
P/BV vs Sector: The company's P/BV (2.66) is lower than that of the sector as a whole (251.23).
P/BV vs Market: The company's P/BV (2.66) is lower than that of the market as a whole (51.56).
5.3.1 P/BV Similar companies
5.5. P/S
P/S vs Sector: The company's P/S indicator (7.01) is lower than that of the sector as a whole (55.96).
P/S vs Market: The company's P/S indicator (7.01) is lower than that of the market as a whole (136.53).
5.5.1 P/S Similar companies
5.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (59.71) is higher than that of the sector as a whole (12.23).
EV/Ebitda vs Market: The company's EV/Ebitda (59.71) is higher than that of the market as a whole (-47.59).
6. Profitability
6.1. Profitability and revenue
6.2. Earnings per share - EPS
6.3. Past profitability Net Income
Yield Trend: Negative and has fallen by -34.03% over the last 5 years.
Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-34.03%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-28.07%).
6.4. ROE
ROE vs Sector: The company's ROE (2.17%) is lower than that of the sector as a whole (103.63%).
ROE vs Market: The company's ROE (2.17%) is higher than that of the market as a whole (-10.64%).
6.6. ROA
ROA vs Sector: The company's ROA (2%) is higher than that of the sector as a whole (-2.84%).
ROA vs Market: The company's ROA (2%) is lower than that of the market as a whole (39.05%).
6.6. ROIC
ROIC vs Sector: The company's ROIC (-4.59%) is lower than that of the sector as a whole (1.17%).
ROIC vs Market: The company's ROIC (-4.59%) is lower than that of the market as a whole (8.76%).
8. Dividends
8.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0.5195%.
8.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
8.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
9. Insider trades
9.1. Insider trading
Insider Selling More insider purchases by 872.81% over the last 3 months.
9.2. Latest transactions
| Transaction date | Insider | Type | Price | Volume | Quantity |
|---|---|---|---|---|---|
| 04.12.2025 | Leite John Chief Commercial Officer-CLIA |
Sale | 47.51 | 6 072 | 1 278 |
| 04.12.2025 | Stapley Marc Chief Executive Officer |
Sale | 47.09 | 36 109 | 7 668 |
| 04.12.2025 | Chambers Rebecca Chief Financial Officer |
Sale | 46.84 | 62 194 | 13 278 |
| 20.11.2025 | Holstein Jens Director |
Sale | 42.36 | 42 360 | 10 000 |
| 20.11.2025 | JENS HOLSTEIN Director |
Purchase | 42.36 | 42 360 | 10 000 |
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
Based on sources: porti.ru
